Post-earnings recap
Reported
Thu, Feb 24, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Edgewise Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 4.61%. The company did not provide revenue figures or future guidance, leaving investors focused on the EPS beat and management's optimistic tone about their pipeline. This performance may bolster investor confidence as they await further developments.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | +6.14% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the quarter's performance, particularly regarding their ongoing projects. They emphasized their commitment to pipeline development.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.